Form 4: Seres Therapeutics Director Dennis A. Ausiello Acquires Stock Options

Director Dennis A. Ausiello acquired stock options for 100,000 shares of Seres Therapeutics common stock on April 10, 2025.

Summary

• On April 10, 2025, Dennis A. Ausiello, a director of Seres Therapeutics, acquired stock options for 100,000 shares.
• The exercise price of the options is $0.58.
• The options vest fully on the earlier of April 10, 2026, or the day before the company's 2026 annual meeting of shareholders.
• The options expire on April 9, 2035.
• Following the transaction, Ausiello directly owns derivative securities for 100,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this is a routine grant.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a change in beneficial ownership for a director of Seres Therapeutics.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Seres Therapeutics, MCRB, stock options, Form 4, director, Ausiello, beneficial ownership, securities